- Home
- MODD vs CUE Comparison
MODD vs CUE Comparison
Compare MODD & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- CUE
- Stock Information
- Founded
- MODD 1998
- CUE 2014
- Country
- MODD United States
- CUE United States
- Employees
- MODD N/A
- CUE N/A
- Industry
- MODD Industrial Specialties
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- CUE Health Care
- Exchange
- MODD Nasdaq
- CUE Nasdaq
- Market Cap
- MODD 46.3M
- CUE 48.0M
- IPO Year
- MODD N/A
- CUE 2018
- Fundamental
- Price
- MODD $0.73
- CUE $0.68
- Analyst Decision
- MODD
- CUE Strong Buy
- Analyst Count
- MODD 0
- CUE 3
- Target Price
- MODD N/A
- CUE $3.00
- AVG Volume (30 Days)
- MODD 193.3K
- CUE 311.2K
- Earning Date
- MODD 06-20-2025
- CUE 08-13-2025
- Dividend Yield
- MODD N/A
- CUE N/A
- EPS Growth
- MODD N/A
- CUE N/A
- EPS
- MODD N/A
- CUE N/A
- Revenue
- MODD N/A
- CUE $7,991,000.00
- Revenue This Year
- MODD N/A
- CUE N/A
- Revenue Next Year
- MODD N/A
- CUE $23.84
- P/E Ratio
- MODD N/A
- CUE N/A
- Revenue Growth
- MODD N/A
- CUE 13.83
- 52 Week Low
- MODD $0.63
- CUE $0.45
- 52 Week High
- MODD $2.65
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- MODD 37.90
- CUE 47.91
- Support Level
- MODD $0.67
- CUE $0.65
- Resistance Level
- MODD $0.79
- CUE $0.71
- Average True Range (ATR)
- MODD 0.08
- CUE 0.08
- MACD
- MODD -0.01
- CUE 0.00
- Stochastic Oscillator
- MODD 16.80
- CUE 38.62
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.